var data={"title":"Fondaparinux: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fondaparinux: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6233?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fondaparinux-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fondaparinux: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708809\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Spinal/Epidural hematomas:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins, heparinoids, or fondaparinux and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants; a history of traumatic or repeated epidural or spinal puncture; or a history of spinal deformity or spinal surgery. Optimal timing between the administration of fondaparinux and neuraxial procedures is not known.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174015\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Arixtra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174016\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Arixtra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174034\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Factor Xa Inhibitor;</li>\n      <li>\n        Pentasaccharide, Synthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174018\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> PT and aPTT are insensitive measures of fondaparinux activity. If unexpected changes in coagulation parameters or major bleeding occur, discontinue fondaparinux.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute DVT/PE treatment: </b>SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;50 kg: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">50 to 100 kg: 7.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;100 kg: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual duration: 5 to 9 days (administered up to 26 days in clinical trials)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute coronary syndrome (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NSTE-ACS: SubQ: 2.5 mg once daily; treat for the duration of hospitalization or until PCI performed (ACC/AHA [Amsterdam 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">STEMI: IV: 2.5 mg once; subsequent doses (starting the following day): SubQ: 2.5 mg once daily; treat for the duration of the hospitalization, up to 8 days, or until revascularization (ACCF/AHA [O&rsquo;Gara 2013]; Yusuf 2006b)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute symptomatic superficial vein thrombosis (&ge;5 cm in length) of the legs (off-label use):</b> SubQ: 2.5 mg once daily for 45 days (Decousus 2010; Guyatt 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute thrombosis (unrelated to HIT) in patients with a past history of HIT (off-label use) (Guyatt 2012; Warkentin 2011a):</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;50 kg: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">50 to 100 kg: 7.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;100 kg: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin induced thrombocytopenia treatment (off-label use)</b> (Grouzi 2010; Lobo 2008; Warkentin 2011b): SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;50 kg: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">50 to 100 kg: 7.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;100 kg: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>VTE prophylaxis:</b> SubQ: Adults &ge;50 kg: 2.5 mg once daily. <b>Note:</b> Prophylactic use contraindicated in patients &lt;50 kg. Initiate dose after hemostasis has been established, no earlier than 6 to 8 hours postoperatively.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>VTE prophylaxis in hospitalized cancer patients (off-label use): </b>SubQ: 2.5 mg once daily; recommended duration of therapy is length of hospital stay or until fully ambulatory (Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>VTE prophylaxis in patients undergoing major surgery for cancer (off-label use): </b>SubQ: 2.5 mg once daily beginning 6 to 8 hours postoperative; treatment duration should be at least 7 to 10 days. Prolonged treatment up to 4 weeks should be considered in patients undergoing major abdominal or pelvic surgery for cancer with high-risk features (eg, limited mobility, obesity, VTE history, comorbid conditions) (Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>VTE prophylaxis with history of HIT (off-label use):</b> SubQ: 2.5 mg once daily (Blackmer 2009; Harenberg 2004; Parody 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual duration: 5 to 9 days (up to 10 days following abdominal surgery or up to 11 days following hip fracture, hip replacement, or knee replacement was administered in clinical trials). The American College of Chest Physicians recommends a minimum of 10 to 14 days for patients undergoing total hip arthroplasty, total knee arthroplasty, or hip fracture surgery; extended duration of up to 35 days suggested (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Transitioning between anticoagulants:</b>\n      <b> Note: </b>This provides general guidance on transitioning between anticoagulants; refer to label and local protocol for additional detail:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transitioning from fondaparinux to another anticoagulant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Transitioning from fondaparinux to unfractionated heparin (UFH) continuous infusion:</i> Start maintenance dose (no bolus) of unfractionated heparin 1 to 2 hours prior to when the next dose of fondaparinux is scheduled to be given (Nutescu 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Transitioning from fondaparinux to non-warfarin oral anticoagulant (NOAC): </i>Start NOAC within 0 to 2 hours of when the next dose of fondaparinux is scheduled to be given (Burnett 2016; Smythe 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Transitioning from fondaparinux to warfarin: </i>Overlap fondaparinux and warfarin until a therapeutic INR has been established. For acute DVT and PE treatment, INR should be &ge;2 for at least 24 hours and parenteral therapy should be continued for at least 5 days for initial treatment (ACCP [Guyatt 2012]; Smythe 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transitioning from another anticoagulant to fondaparinux:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Transitioning from UFH continuous infusion to fondaparinux:</i> Start fondaparinux within one hour after UFH continuous infusion has been stopped (Nutescu 2007) (consult local protocol if aPTT is above the target range).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Transitioning from NOAC to fondaparinux:</i> Start fondaparinux at the time when the next dose of NOAC would have been given (Bauer 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Transitioning from warfarin to fondaparinux:</i> Discontinue warfarin and initiate fondaparinux as soon as INR becomes subtherapeutic (Bauer 2018).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174019\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174020\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling. Total clearance is reduced ~25% compared to patients with normal renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 30 to 50 mL/minute: Use caution; total clearance ~40% lower compared to patients with normal renal function. When used for thromboprophylaxis, the American College of Chest Physicians suggests a 50% reduction in dose or use of low-dose heparin instead of fondaparinux (Garcia 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable: Yes; clearance increased by 20% (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9537831\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild-to-moderate impairment (Child-Pugh class A and B): No dosage adjustment necessary; monitor for signs of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustment provided in the manufacturer's labeling (has not been studied). Use with caution; monitor closely for signs of bleeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173990\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.4 mL (0.4 mL); 7.5 mg/0.6 mL (0.6 mL); 10 mg/0.8 mL (0.8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arixtra: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.4 mL (0.4 mL); 7.5 mg/0.6 mL (0.6 mL); 10 mg/0.8 mL (0.8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.4 mL (0.4 mL); 7.5 mg/0.6 mL (0.6 mL); 10 mg/0.8 mL (0.8 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173976\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173994\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: For SubQ administration; do <b>not</b> administer IM. Alternate injection sites. Do not expel air bubble from syringe before injection. Administer according to recommended regimen; when used for DVT prophylaxis, early initiation (before 6 hours after orthopedic surgery) has been associated with increased bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: For STEMI patients (off-label use) may administer initial dose as IV push or mix in NS and infuse over 1 to 2 minutes; flush tubing with NS after infusion to ensure complete administration for fondaparinux.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">To convert from IV unfractionated heparin (UFH) infusion to SubQ fondaparinux (Nutescu 2007): Calculate specific dose for fondaparinux based on indication, discontinue UFH, and begin fondaparinux within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">To convert from SubQ fondaparinux to IV UFH infusion (Nutescu 2007): Discontinue fondaparinux; calculate specific dose for IV UFH infusion based on indication; omit heparin bolus/loading dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>For subQ fondaparinux dosed every 24 hours:</i> Start IV UFH infusion 22 to 23 hours after last dose of fondaparinux</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173993\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute deep vein thrombosis:</b> Treatment of acute DVT in conjunction with warfarin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute pulmonary embolism:</b> Treatment of acute PE in conjunction with warfarin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Venous thromboembolism:</b> Prophylaxis of venous thromboembolism (VTE)  in patients undergoing surgery for hip replacement, knee replacement, hip fracture (including extended prophylaxis following hip fracture surgery), or abdominal surgery (in patients at risk for thromboembolic complications).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474758\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute coronary syndrome (non-ST-elevation acute coronary syndrome [NSTE-ACS] or ST-elevation myocardial infarction [STEMI]); Acute symptomatic superficial vein thrombosis (&ge;5 cm in length) of the legs; Acute thrombosis (unrelated to heparin induced thrombocytopenia [HIT]) (history of HIT); HIT treatment; Venous thromboembolism prophylaxis (history of HIT); Venous thromboembolism prophylaxis in general surgery; Venous thromboembolism prophylaxis in hospitalized cancer patients; Venous thromboembolism prophylaxis in patients undergoing major surgery for cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174539\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arixtra may be confused with Aristada, Arista AH (hemostatic device)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173981\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all anticoagulants, bleeding is the major adverse effect. Hemorrhage may occur at any site. Risk appears increased by a number of factors including renal dysfunction, age (&gt;75 years), and weight (&lt;50 kg). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Hematologic &amp; oncologic: Anemia (2% to 20%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypotension (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Insomnia (&le;5%), dizziness (&le;4%), confusion (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Increased wound secretion (&le;5%), skin blister (&le;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypokalemia (&le;4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Purpura (&le;4%), thrombocytopenia (50,000 to 100,000/mm<sup>3</sup>: 3%), hematoma (2% to 3%), minor hemorrhage (2% to 3%), major hemorrhage (1% to 3%; risk of major hemorrhage increased as high as 5% in patients receiving initial dose &lt;6 hours following surgery), postoperative hemorrhage (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum ALT (&gt;3 &times; ULN: 1% to 3%), increased serum AST (&gt;3 &times; ULN: &lt;1% to &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: postoperative wound infection (abdominal surgery: 5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Epistaxis (VTE: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, angioedema, catheter site thrombosis (during PCI; without heparin), elevated aPTT associated with bleeding, epidural hematoma, hemorrhagic death, injection site reaction (bleeding at injection site, skin rash, pruritus), intracranial hemorrhage, reoperation due to bleeding, severe thrombocytopenia (&lt;50,000/mm<sup>3</sup>), spinal hematoma, thrombocytopenia (with thrombosis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173997\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Serious hypersensitivity (eg, angioedema, anaphylactoid/anaphylactic reactions) to fondaparinux or any component of the formulation; severe renal impairment (CrCl &lt;30 mL/minute); body weight &lt;50 kg (prophylaxis); active major bleeding; bacterial endocarditis; thrombocytopenia associated with a positive <i>in vitro</i> test for antiplatelet antibody in the presence of fondaparinux</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173979\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative and angiodysplastic GI disease; uncontrolled arterial hypertension; hemorrhagic stroke; recent intracranial hemorrhage; use shortly after brain, spinal, or ophthalmology surgery; in patients treated concomitantly with platelet inhibitors; thrombocytopenia or platelet defects; renal impairment; diabetic retinopathy; and/or patients &lt;50 kg. Risk of major bleeding may be increased if initial dose is administered earlier than recommended (initiation recommended at 6 to 8 hours following surgery). Do not administer with other agents that increase the risk of hemorrhage unless they are essential for the management of the underlying condition (eg, vitamin K antagonists for treatment of VTE). PT and aPTT are insensitive measures of fondaparinux activity. If unexpected changes in coagulation parameters or major bleeding occur, discontinue fondaparinux (elevated aPTT associated with bleeding events have been reported in postmarketing data).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Has occurred with administration, including very rare reports of thrombocytopenia with thrombosis similar to heparin-induced thrombocytopenia (HIT); however, has been used in patients with current or history of HIT due to a lack of an immune-mediated effect on platelets (ACCP [Guyatt 2012]; Savi 2005). Use is contraindicated in patients with thrombocytopenia associated with a positive in vitro test for antiplatelet antibodies in the presence of fondaparinux. Monitor patients closely and discontinue therapy if platelets fall to &lt;100,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: May increase the risk of bleeding in patients with hepatic impairment. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: May increase the risk of bleeding in patients with renal impairment. Use with caution in patients with CrCl 30 to 50 mL/minute (may cause prolonged anticoagulation); contraindicated in patients with CrCl &lt;30 mL/minute. Periodically monitor renal function; discontinue immediately if severe renal impairment develops.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; increased risk of bleeding in patients &gt;75 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &lt;50 kg: In patients &lt;50 kg, clearance of fondaparinux is reduced by 30% and the risk of bleeding is increased; use with caution; dosage reduction recommended. Contraindicated in patients &lt;50 kg when used as prophylactic therapy for patients undergoing hip fracture, hip replacement, or knee replacement surgery, or abdominal surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The needle guard may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For subcutaneous administration; not for IM administration. For STEMI patients (off-label use) may administer initial dose IV. Do not use interchangeably (unit for unit) with low molecular weight heparins, heparin, or heparinoids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation: Following discontinuation, the anticoagulant effects of fondaparinux may persist for 2 to 4 days and even longer in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuraxial anesthesia:<b> [US Boxed Warning]: Spinal or epidural hematomas, including subsequent long-term or permanent paralysis, may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients anticoagulated with LMWH, heparinoids, or fondaparinux.</b> <b>Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis (such as NSAIDS, platelet inhibitors, or other anticoagulants), the use of indwelling epidural catheters, a history of spinal deformity or spinal surgery, as well as a history of traumatic or repeated epidural or spinal punctures.</b> <b>Optimal timing between administration of fondaparinux and neuraxial procedures is not known. <b>Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary. Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.</b></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Percutaneous coronary intervention (PCI): The administration of fondaparinux as the sole anticoagulant is <b>not recommended</b> during PCI due to an increased risk for guiding-catheter thrombosis. Use of an anticoagulant with antithrombin activity (eg, unfractionated heparin) is recommended as adjunctive therapy to PCI even if prior treatment with fondaparinux (must take into account whether GP IIb/IIIa antagonists have been administered) (ACC/AHA [Amsterdam 2014]; Levine 2011). Use of fondaparinux during primary PCI is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299363\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173983\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8691&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173999\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on case reports, small amounts of fondaparinux have been detected in the umbilical cord following multiple doses during pregnancy (Dempfle 2004). Use of fondaparinux in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14050079\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if fondaparinux is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. The use of alternative anticoagulants is preferred (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173988\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periodically monitor CBC, platelet count, serum creatinine, and occult blood testing of stools. Anti-Xa activity of fondaparinux can be measured by the assay if fondaparinux is used as the calibrator.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In patients undergoing neuraxial procedures, monitor for signs/symptoms of neurologic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14050080\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Routine monitoring is not recommended; the following fondaparinux-specific anti-Xa concentrations have been reported (Garcia 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thromboprophylaxis dose: Anti-Xa activity at 3 hours post dose: ~0.39 to 0.5 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic dosing (eg, 7.5 mg once daily): Anti-Xa activity at 3 hours post dose: 1.2 to 1.26 mg/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173978\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fondaparinux is a synthetic pentasaccharide that causes an antithrombin III-mediated selective inhibition of factor Xa. Neutralization of factor Xa interrupts the blood coagulation cascade and inhibits thrombin formation and thrombus development.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173996\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: SubQ: Rapid and complete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 7 to 11 L; mainly in blood </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &ge;94% to antithrombin III </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 17 to 21 hours; prolonged with renal impairment and in the elderly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: SubQ: ~2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (up to 77%, unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422230\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Arixtra Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/0.5 mL (0.5 mL): $66.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/0.4 mL (0.4 mL): $157.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg/0.6 mL (0.6 mL): $157.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.8 mL (0.8 mL): $157.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fondaparinux Sodium Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/0.5 mL (0.5 mL): $57.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/0.4 mL (0.4 mL): $135.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg/0.6 mL (0.6 mL): $135.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.8 mL (0.8 mL): $135.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174000\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arixtra (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, GY, HN, HR, HU, ID, IE, IL, IN, IS, IT, JM, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, PA, PE, PH, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SR, SV, TH, TR, TT, TW, UY, VN);</li>\n      <li>Arykstra (UA);</li>\n      <li>Quixidar (AT, BE, BG, CH, CZ, DE, DK, EE, FR, GB, IT, MT, NL, NO, PL, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arixtra (fondaparinux) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arixtra (fondaparinux) [product monograph]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer KA, Eriksson BI, Lassen MR, et al, &ldquo;Fondaparinux Compared With Enoxaparin for the Prevention of Venous Thromboembolism After Elective Major Knee Surgery,&rdquo; <i>N Engl J Med</i>, 2001, 345:1305-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/11794149/pubmed\" target=\"_blank\" id=\"11794149\">11794149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer KA, &ldquo;Fondaparinux Sodium: A Selective Inhibitor of Factor Xa,&rdquo; <i>Am J Health Syst Pharm</i>, 2001, 58(Suppl 2):14-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer K. Fondaparinux: Dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 13, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19737996\"></a>Blackmer AB, Oertel MD, and Valgus JM, &ldquo;Fondaparinux and the Management of Heparin-induced Thrombocytopenia: The Journey Continues,&rdquo; <i>Ann Pharmacother</i>, 2009, 43(10):1636-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/19737996/pubmed\" target=\"_blank\" id=\"19737996\">19737996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buller HR, Davidson BL, Decousus H, et al, &ldquo;Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis: A Randomized Trial,&rdquo; <i>Ann Intern Med</i>, 2004, 140(11):867-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/15172900/pubmed\" target=\"_blank\" id=\"15172900\">15172900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buller HR, Davidson BL, Decousus H, et al, &ldquo;Subcutaneous Fondaparinux Versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism,&rdquo; <i>N Engl J Med</i>, 2003, 349(18):1695-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/14585937/pubmed\" target=\"_blank\" id=\"14585937\">14585937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. <i>J Thromb Thrombolysis.</i> 2016;41(1):206-232. doi: 10.1007/s11239-015-1310-1317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/26780747/pubmed\" target=\"_blank\" id=\"26780747\">26780747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20860504\"></a>Decousus H, Prandoni P, Mismetti P, et al, &ldquo;Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs,&rdquo; <i>N Engl J Med</i>, 2010, 363(13):1222-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/20860504/pubmed\" target=\"_blank\" id=\"20860504\">20860504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dempfle CE, &ldquo;Minor Transplacental Passage of Fondaparinux <i>in vivo</i>,&rdquo; <i>N Engl J Med</i>, 2004, 350(18):1914-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/15115845/pubmed\" target=\"_blank\" id=\"15115845\">15115845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eriksson BI, Bauer KA, Lassen MR, et al, &ldquo;Fondaparinux Compared With Enoxaparin for the Prevention of Venous Thromboembolism After Hip-Fracture Surgery,&rdquo; <i>N Engl J Med</i>, 2001, 345:1298-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/11794148/pubmed\" target=\"_blank\" id=\"11794148\">11794148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):24-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21883881\"></a>Goldfarb MJ, Blostein MD. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. <i>J Thromb Haemost.</i> 2011;9(12):2501-2503. doi: 10.1111/j.1538-7836.2011.04489.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/21883881/pubmed\" target=\"_blank\" id=\"21883881\">21883881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19825921\"></a>Grouzi E, Kyriakou E, Panagou I, et al. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.<i> Clin Appl Thromb Hemost.</i> 2010;16(6):663-667. doi: 10.1177/1076029609347900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/19825921/pubmed\" target=\"_blank\" id=\"19825921\">19825921</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15339691\"></a>Harenberg J, Jorg I, and Fenyvesi T, &ldquo;Treatment of Heparin-induced Thrombocytopenia With Fondaparinux,&rdquo; <i>Haematologica</i>, 2004, 89(8):1017-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/15339691/pubmed\" target=\"_blank\" id=\"15339691\">15339691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25515959\"></a>Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study.<i> Blood.</i> 2015;125(6):924-929. doi: 10.1182/blood-2014-09-599498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/25515959/pubmed\" target=\"_blank\" id=\"25515959\">25515959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22315268\"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest.</i> 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18217156\"></a>Lobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.<i> Thromb Haemost.</i> 2008;99(1):208-214. doi: 10.1160/TH07-04-0252.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/18217156/pubmed\" target=\"_blank\" id=\"18217156\">18217156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman GH, Bohlke K, Khorana AA, et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. <i>J Clin Oncol</i>. 2015;33(6):654-656. doi: 10.1200/JCO.2014.59.7351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/25605844/pubmed\" target=\"_blank\" id=\"25605844\">25605844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman GH, Khorana AA, Kuderer NM, et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2013;31(17):2189-2204. doi: 10.1200/JCO.2013.49.1118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/23669224/pubmed\" target=\"_blank\" id=\"23669224\">23669224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu EA and Dager W, &ldquo;Heparin, Low Molecular Weight Heparin, and Fondaparinux,&rdquo; <i>Managing Anticoagulation Patients in the Hospital</i>, Gulseth M ed, American Society of Health-System Pharmacists, Bethesda, MD: 2007, 181.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14607764\"></a>Parody R, Oliver A, Souto JC, et al, &ldquo;Fondaparinux (Arixtra&reg;), as an Alternative Antithrombotic Prophylaxis When There is Hypersensitivity to Low Molecular Weight and Unfractionated Heparins,&rdquo; <i>Haematologica</i>, 2003, 88(11):ECR32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/14607764/pubmed\" target=\"_blank\" id=\"14607764\">14607764</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Savi P, Chong BH, Greinacher A, et al, &ldquo;Effect of Fondaparinux on Platelet Activation in the Presence of Heparin-Dependent Antibodies: A Blinded Comparative Multicenter Study With Unfractionated Heparin,&rdquo; <i>Blood</i>, 2005, 105(1):139-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/15388575/pubmed\" target=\"_blank\" id=\"15388575\">15388575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29169470\"></a>Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia.<i> J Am Coll Cardiol.</i> 2017;70(21):2636-2648. doi: 10.1016/j.jacc.2017.09.1099.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/29169470/pubmed\" target=\"_blank\" id=\"29169470\">29169470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smythe MA, Priziola J, Dobesh PP, et al. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. <i>J Thromb Thrombolysis.</i> 2016;41(1):165-186. doi: 10.1007/s11239-015-1315-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/26780745/pubmed\" target=\"_blank\" id=\"26780745\">26780745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21393394\"></a>Warkentin TE, Davidson BL, Buller HR, et al, &ldquo;Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE,&rdquo; <i>Chest</i>, 2011a, 140(2):366-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/21393394/pubmed\" target=\"_blank\" id=\"21393394\">21393394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warkentin TE, Maurer BT, and Aster RH, &ldquo;Heparin-Induced Thrombocytopenia Associated With Fondaparinux,&rdquo; <i>N Engl J Med</i>, 2007, 356(25):2653-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/17582083/pubmed\" target=\"_blank\" id=\"17582083\">17582083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21883878\"></a>Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. <i>J Thromb Haemost.</i> 2011b;9(12):2389-2396. doi: 10.1111/j.1538-7836.2011.04487.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/21883878/pubmed\" target=\"_blank\" id=\"21883878\">21883878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16537663\"></a>Yusuf S, Mehta SR, Chrolavicius S, et al, &ldquo;Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes &minus; The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators,&rdquo; <i>N Engl J Med</i>, 2006a, 354(14):1464-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/16537663/pubmed\" target=\"_blank\" id=\"16537663\">16537663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16537725\"></a>Yusuf S, Mehta SR, Chrolavicius S, et al, &ldquo;Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial,&rdquo; <i>JAMA</i>, 2006b, 295(13):1519-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fondaparinux-drug-information/abstract-text/16537725/pubmed\" target=\"_blank\" id=\"16537725\">16537725</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8691 Version 191.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708809\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F174015\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F174016\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F174034\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F174018\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F174019\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F174020\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9537831\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F173990\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F173976\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F173994\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F173993\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474758\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174539\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F173981\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F173997\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F173979\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299363\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F173983\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F173999\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14050079\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F173988\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F14050080\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F173978\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F173996\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422230\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F174000\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8691|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fondaparinux-patient-drug-information\" class=\"drug drug_patient\">Fondaparinux: Patient drug information</a></li></ul></div></div>","javascript":null}